Leptospirosis (Weil's Disease)

1. Clinical Overview

Leptospirosis is a spirochaetal zoonosis of global significance, representing the most common zoonotic infection worldwide with an estimated 1.03 million cases and 58,900 deaths annually. [1] The causative agent, Leptospira interrogans (and related pathogenic species), is transmitted through contact with water or soil contaminated by the urine of infected animals, predominantly rats.

The clinical spectrum ranges from a mild, self-limiting febrile illness (90% of cases) to severe multi-organ failure known as Weil's disease (10% of cases), characterized by the classical triad of jaundice, acute kidney injury, and hemorrhage. [2] Case fatality rates vary from 5-15% in severe disease, but can exceed 50% when complicated by pulmonary hemorrhage syndrome. [3]

The infection represents a significant occupational health hazard for farmers, sewage workers, veterinarians, and military personnel, but is increasingly recognized in recreational water sport enthusiasts following flooding or freshwater immersion activities. [4] Early recognition and prompt antibiotic therapy significantly improve outcomes, making leptospirosis a critical diagnosis in returning travelers with fever and potential water exposure.

Clinical Pearls

Conjunctival Suffusion: This pathognomonic sign presents as bilateral conjunctival redness without purulent discharge, typically appearing on days 3-4 of illness. Unlike bacterial conjunctivitis, there is no "sticky eye" or mucopurulent exudate. The suffusion results from conjunctival capillary vasculitis and occurs in 30-99% of cases, making it the single most discriminating clinical feature. [5]

The "Calf Pain" Clue: Severe myalgia localized to the gastrocnemius muscles and lumbar region is highly characteristic, present in up to 90% of cases. [6] The pain can be intense enough to mimic rhabdomyolysis or acute surgical abdomen. Patients may be unable to walk due to calf tenderness. This distinguishes leptospirosis from dengue fever, where myalgia is more generalized.

Biphasic Illness Pattern: The disease classically follows a "saddle-back" fever curve, though this occurs in only 30-50% of cases. [7]

• Phase 1 (Septic/Leptospiremic): Days 1-7. High fever, myalgia, headache. Spirochaetes detectable in blood and CSF.
• Defervescence: Days 7-9. Brief afebrile period with clinical improvement.
• Phase 2 (Immune/Leptospiruric): Days 10-14. Fever recurrence with organ complications (meningitis, uveitis, renal failure). Spirochaetes found in urine and tissues. Antibody response detectable.

---

2. Epidemiology

Global Distribution

Leptospirosis occurs worldwide but demonstrates marked geographic variation, with highest incidence in tropical and subtropical regions where environmental conditions favor leptospiral survival. [8]

Demographics

• Age: Can affect all ages; highest incidence in working-age adults (20-40 years) due to occupational/recreational exposure [9]
• Sex: Male predominance (4:1 ratio) reflecting occupational exposure patterns [1]
• Seasonality: Strong seasonal variation with peaks following heavy rainfall, flooding, and monsoon seasons
• Urban vs Rural: Traditionally rural disease, but increasing urban incidence in tropical cities with rodent populations and poor sanitation [10]

Risk Factors

Occupational Exposures (70% of cases in temperate regions): [11]

• Agriculture/farming (rice paddies, livestock)
• Sewage and sanitation workers
• Veterinarians and abattoir workers
• Mining and military personnel
• Fish farm workers

Recreational Exposures (increasing incidence): [4]

• Freshwater swimming, kayaking, canoeing
• Triathlons (especially open-water swimming segments)
• Canyoning and adventure tourism
• Fishing
• Post-disaster relief work

Environmental Risk Factors:

• Flooding and natural disasters
• Inadequate sanitation and waste management
• High rodent populations
• Tropical climate with heavy rainfall
• Subsistence farming in endemic areas

Animal Reservoirs

Leptospires establish chronic renal colonization in numerous mammalian species, with asymptomatic shedding in urine: [12]

• Primary: Brown rat (Rattus norvegicus) - maintenance host for L. icterohaemorrhagiae
• Domestic animals: Dogs, cattle, pigs - maintenance hosts for different serovars
• Wildlife: Possums, raccoons, deer, mongoose
• Marine mammals: Seals, sea lions (marine leptospirosis variant)

---

3. Aetiology & Pathophysiology

Microbiology

Leptospira are spiral-shaped bacteria (6-20 μm × 0.1 μm) belonging to the order Spirochaetales. The genus comprises at least 64 species, with 14 pathogenic species. [13]

Clinically Important Species:

• L. interrogans sensu stricto (most common cause of human disease)
• L. borgpetersenii
• L. kirschneri
• L. santarosai
• L. noguchii

The species are further classified into > 300 serovars based on antigenic differences. Major disease-causing serovars include:

• Icterohaemorrhagiae - severe icteric disease (Weil's disease)
• Canicola - canicola fever
• Hardjo - dairy farmers
• Pomona - pig farmers
• Grippotyphosa - freshwater exposure

Transmission

Primary Route: Direct or indirect contact with urine of infected animals

• Spirochaetes enter through mucous membranes (conjunctiva, nasopharynx) or abraded/macerated skin
• Intact skin is generally impermeable, but prolonged immersion causes maceration
• Incubation period: typically 7-12 days (range 2-30 days) [14]

Rare Routes:

• Animal bites (uncommon)
• Ingestion of contaminated water/food
• Human-to-human transmission (extremely rare; case reports in breast milk, sexual contact)
• Vertical transmission (transplacental)

Pathophysiology

The pathogenesis of severe leptospirosis involves complex interactions between bacterial virulence factors and host immune responses. [15]

Initial Infection & Dissemination

1. Breach of epithelial barrier: Leptospires utilize corkscrew motility and multiple adhesins (LigA, LigB, Lsa proteins) to penetrate epithelium
2. Hematogenous dissemination: Leptospiremia occurs within hours, with spirochaetes reaching all organs
3. Immune evasion: Leptospires resist complement-mediated killing through acquisition of host complement regulators (Factor H)

Vascular Injury - Central Mechanism

The hallmark pathology is widespread capillary endothelial damage, but notably WITHOUT significant vasculitis or thrombosis on histopathology. [16]

Mechanisms of endothelial injury:

• Direct bacterial toxins (glycolipoprotein, lipopolysaccharide-like molecules)
• Host inflammatory response (TNF-α, IL-6, IL-1β)
• Endothelial adhesion and bacterial translocation
• Increased vascular permeability

Organ-Specific Pathology

Kidneys (90% of severe cases): [17]

• Tubulointerstitial nephritis - primary lesion
• Proximal tubular necrosis (similar to ATN)
• Interstitial edema and lymphocytic infiltration
• Leptospires persist in proximal tubular lumen
• Key paradox: Severe functional impairment despite relatively preserved tubular architecture
• Results in: Non-oliguric or oliguric AKI, hypokalemia (tubular potassium wasting), hypophosphatemia

Liver: [2]

• Hepatocellular disruption WITHOUT massive necrosis
• Centrizonal cholestasis
• Kupffer cell hyperplasia
• Dissociation between liver architecture (preserved) and function (severely impaired)
• Key paradox: Profound hyperbilirubinemia (often > 500 μmol/L) with only modest transaminase elevation (less than 200 U/L)
• Mechanism: Impaired hepatocyte bilirubin excretion due to disruption of canalicular transporters

Lungs (20-70% of severe cases): [18]

• Diffuse alveolar hemorrhage (pulmonary hemorrhage syndrome)
• Capillary endothelial damage → alveolar-capillary leak
• Intra-alveolar hemorrhage without significant inflammatory infiltrate
• Can progress to ARDS
• Most lethal complication with mortality > 50%

Cardiovascular:

• Myocarditis (subclinical in many cases)
• Arrhythmias (atrial fibrillation, ventricular ectopy)
• Coronary arteritis (rare)
• Myocardial hemorrhage
• Shock (hypovolemic + distributive components)

Skeletal Muscle: [6]

• Myositis with muscle fiber necrosis
• Elevated creatine kinase
• Rarely progresses to true rhabdomyolysis
• Mechanism: Direct invasion + inflammatory response

Central Nervous System:

• Aseptic meningitis (50-90% of cases with CNS involvement) [19]
• Lymphocytic pleocytosis (typically 10-1000 cells/μL)
• Normal glucose, mildly elevated protein
• Leptospires cross blood-brain barrier
• Encephalitis (rare)

Eyes:

• Acute: Conjunctival suffusion (capillary vasculitis)
• Subacute/chronic: Uveitis (anterior > posterior)
• Immune-mediated; occurs weeks-months after acute infection
• Can lead to permanent visual impairment

Hemorrhagic Manifestations

Bleeding results from multifactorial mechanisms: [20]

• Thrombocytopenia (50-90% of severe cases)
  • Peripheral consumption
  • Bone marrow suppression
  • Immune-mediated destruction
• Platelet dysfunction (impaired aggregation)
• Capillary fragility (endothelial damage)
• DIC (in severe cases)
• Vitamin K deficiency (cholestasis)

---

4. Clinical Presentation

Spectrum of Disease

Leptospirosis presents across a clinical spectrum determined by bacterial virulence, inoculum size, host immunity, and serovar. [21]

Anicteric Leptospirosis (90% of cases)

The mild, self-limiting form often misdiagnosed as viral syndrome or dengue fever.

Typical Features:

• Abrupt onset high fever (38-40°C) with rigors
• Severe headache - retro-orbital, frontal, may mimic meningitis
• Myalgia - especially calves (90%), lower back, thighs
  • Intensity peaks at days 3-4
  • Can prevent ambulation
• Conjunctival suffusion (30-99%) - appears day 3-4
• Nausea and vomiting (50-90%)
• Photophobia (30%)

Physical Examination:

• Fever (> 38.5°C)
• Conjunctival suffusion (pathognomonic when present)
• Muscle tenderness (especially gastrocnemius)
• Relative bradycardia (occasional)
• Hepatomegaly (20%)
• Lymphadenopathy (10%)
• Splenomegaly (less than 10%)

Course:

• Fever duration: 5-7 days
• Spontaneous resolution in most cases
• Fatigue may persist for weeks

Icteric Leptospirosis - Weil's Disease (5-10% of cases)

Severe multi-organ disease with significant mortality. [2]

Classical Weil's Triad:

1. Jaundice - deep orange/bronze hue
2. Acute kidney injury - oliguria/anuria
3. Hemorrhage - from multiple sites

Clinical Features:

Hepatic:

• Jaundice (> 90% of severe cases)
• Typically appears day 4-6
• Profound hyperbilirubinemia (often > 300-500 μmol/L)
• Hepatomegaly (tender)
• No asterixis (synthetic function relatively preserved)

Renal:

• Oliguria/anuria (60%)
• Non-oliguric renal failure (40%)
• Flank pain (occasional)
• Hypovolemia (third-spacing)

Hemorrhagic:

• Petechiae, purpura, ecchymoses
• Epistaxis
• Hemoptysis (pulmonary hemorrhage - poor prognostic sign)
• Gastrointestinal bleeding (hematemesis, melena)
• Hematuria
• Subconjunctival hemorrhage
• Rarely: CNS hemorrhage

Pulmonary:

• Cough (often dry initially)
• Dyspnea
• Hemoptysis (ominous sign)
• Diffuse alveolar hemorrhage → ARDS
• Bilateral crackles on auscultation
• Severe hypoxemia

Cardiovascular:

• Hypotension/shock
• Arrhythmias
• Chest pain (myocarditis)
• Congestive heart failure (rare)

Neurological:

• Aseptic meningitis (40-90% of severe cases)
• Neck stiffness
• Altered consciousness (encephalitis - rare)
• Seizures (rare)
• Peripheral neuropathy (late)

Dermatological:

• Jaundice
• Petechiae/ecchymoses (50%)
• Maculopapular rash (rare)
• Desquamation (convalescent phase)

Special Presentations

Pulmonary Hemorrhage Syndrome (SPHS)

The most lethal complication with mortality 50-70%. [18]

Clinical Features:

• Occurs days 3-9 of illness
• Sudden onset dyspnea
• Hemoptysis (may be massive)
• Severe hypoxemia
• Bilateral infiltrates on chest X-ray
• Rapid progression to respiratory failure

Risk Factors:

• Male sex
• Chronic alcohol use
• Delayed presentation
• Specific serovars (L. interrogans serovar Icterohaemorrhagiae)

Myocarditis

Present in up to 50% of severe cases but often subclinical. [22]

Manifestations:

• Arrhythmias (most common)
  • Atrial fibrillation
  • Ventricular ectopy
  • Heart block (rare)
• Heart failure (rare)
• Chest pain
• ECG changes: ST-T wave abnormalities, prolonged QT

Aseptic Meningitis

Occurs in 40-90% of patients with severe disease. [19]

CSF Findings:

• Pleocytosis: 10-1000 cells/μL (lymphocyte predominant)
• Normal or mildly elevated protein (less than 1 g/L)
• Normal glucose (> 50% serum glucose)
• Leptospires may be cultured (rarely positive)

---

5. Differential Diagnosis

Leptospirosis is the "great imitator" among infectious diseases, mimicking numerous conditions. [23]

Priority Differentials

"Cannot Miss" Diagnoses

In the acutely unwell patient with suspected leptospirosis, always consider:

1. Meningococcal sepsis - rapid progression, purpuric rash, shock
2. Malaria - in returning traveler from endemic area
3. Acute hepatic failure - encephalopathy, coagulopathy
4. Septic shock - localizing infection source

---

6. Investigations

Diagnostic Approach: Timing Is Critical

Leptospiral diagnostic tests have time-dependent sensitivity based on the immune/septic phase. [24]

Specific Diagnostic Tests

Molecular Diagnosis

PCR (Polymerase Chain Reaction) - Test of Choice in First Week [25]

• Samples: Blood (days 1-10), urine (after day 7), CSF (if meningitis)
• Sensitivity: 60-80% in first week
• Advantages: Rapid (24-48 hours), detects early infection
• Limitations: Requires specialized labs, sensitivity declines after day 10

Serological Diagnosis

Microscopic Agglutination Test (MAT) - Gold Standard Serological Test [24]

• Principle: Live leptospires agglutinate in presence of specific antibodies
• Method: Serial dilutions against panel of serovars
• Diagnostic criteria:
  • "Single titer ≥1:400 in endemic area (suggestive)"
  • ≥1:800 in non-endemic area (diagnostic)
  • 4-fold rise between acute and convalescent sera (definitive)
• Timing: Antibodies appear day 5-7, peak at week 3-4
• Limitations:
  • Requires paired samples (2-week interval)
  • Labor-intensive, requires live cultures
  • Not widely available
  • Previous infection/vaccination can cause positive results

ELISA (IgM/IgG) - Point-of-Care Alternative

• IgM ELISA: Sensitivity 80-90% after day 7; more widely available than MAT
• Advantages: Rapid, easier to perform, single sample
• Limitations: Less specific than MAT, cannot determine serovar

Lateral Flow Immunoassay (Rapid Tests)

• Sensitivity: 60-80%; Specificity: 90-95%
• Advantages: Bedside test, 15-minute result
• Limitations: Lower sensitivity than laboratory tests
• Use: Resource-limited settings, screening

Culture

Blood/CSF/Urine Culture

• Media: Requires specialized media (EMJH - Ellinghausen-McCullough-Johnson-Harris)
• Growth time: 6-16 weeks
• Sensitivity: 30-50% (low)
• Utility: Research/epidemiology; impractical for acute diagnosis
• Advantage: Allows serovar identification

Routine Laboratory Investigations

Hematology

Biochemistry

Characteristic Pattern: Profound cholestatic jaundice with minimal hepatocellular injury

• Bilirubin > 500 μmol/L
• ALT less than 200 U/L
• This pattern distinguishes leptospirosis from viral hepatitis (where ALT >> 1000)

Urinalysis

• Proteinuria (90%)
• Hematuria (micro or macroscopic)
• Pyuria (sterile)
• Granular casts (tubular injury)
• Hyaline casts

Coagulation Studies

• Prolonged PT/APTT (cholestasis, DIC)
• Elevated D-dimer
• Low fibrinogen (if DIC)

Imaging

Chest X-Ray

Findings in pulmonary involvement:

• Bilateral patchy alveolar infiltrates (snowstorm appearance)
• Diffuse alveolar hemorrhage pattern
• ARDS picture in severe cases
• Pleural effusions (30%)

Progression: Can deteriorate rapidly over 12-24 hours

Ultrasound Abdomen

• Hepatomegaly
• Splenomegaly (less common)
• Assess for ascites (third-spacing)

CT Imaging

Usually not required for diagnosis, but may show:

• Hepatomegaly
• Renal enlargement (acute tubular injury)
• Pulmonary consolidation/ground-glass opacities

---

7. Management

Overview: Time-Critical Intervention

Early antibiotic therapy improves outcomes, particularly if initiated within 5 days of symptom onset. [26] Management is stratified by severity.

Risk Stratification

---

Antibiotic Therapy

Mild to Moderate Disease (Outpatient/Ward)

First-Line: Oral Doxycycline [27]

• Dose: 100 mg PO twice daily
• Duration: 7 days
• Evidence: Multiple RCTs demonstrate efficacy
• Advantages: Excellent tissue penetration, once-daily dosing option
• Contraindications: Pregnancy, children less than 8 years

Alternative: Oral Amoxicillin

• Dose: 500-1000 mg PO three times daily
• Duration: 7 days
• Use: Pregnancy, pediatrics, doxycycline intolerance

Alternative: Azithromycin

• Dose: 500 mg PO once daily (or 1 g single dose)
• Duration: 3-5 days
• Evidence: Limited but appears effective
• Use: Compliance concerns, resource-limited settings

Severe Disease (ICU/HDU)

First-Line: Intravenous Penicillin G [26]

• Dose: 1.5 million units (approximately 1.2 g) IV every 6 hours
• Alternative dosing: 6-12 million units/day by continuous infusion
• Duration: 7 days (can switch to oral after clinical improvement)
• Evidence: Standard of care based on historical data and observational studies

Alternative: Ceftriaxone

• Dose: 1-2 g IV once daily
• Duration: 7 days
• Advantages: Once-daily dosing, excellent CSF penetration (if meningitis)
• Evidence: Non-inferiority to penicillin in RCTs [28]

Alternative: Cefotaxime

• Dose: 1 g IV every 6 hours
• Duration: 7 days

Penicillin Allergy:

• Doxycycline IV: 100 mg every 12 hours
• Aztreonam (if severe allergy)

Jarisch-Herxheimer Reaction

Incidence: 10-30% of patients within 2-4 hours of first antibiotic dose [29]

Clinical Features:

• Fever spike (> 1°C increase)
• Rigors
• Hypotension
• Tachycardia
• Headache worsening
• Myalgia exacerbation

Mechanism: Massive endotoxin release from dying spirochaetes

Management:

• Anticipation and monitoring - vital signs every 30 minutes for first 4 hours
• Supportive care (fluids, antipyretics)
• Does NOT require antibiotic cessation
• Usually self-limiting (4-6 hours)
• Rare severe cases: Consider corticosteroids (methylprednisolone 40 mg IV) - evidence limited

---

Supportive Care

Fluid Management

Challenges:

• Hypovolemia (vomiting, third-spacing, renal losses)
• Capillary leak (risk of pulmonary edema)
• Oliguric AKI (fluid overload risk)

Approach:

• Early resuscitation: Crystalloids (normal saline, Hartmann's)
• Monitor: CVP, urine output, lactate
• Caution: Avoid aggressive fluids if pulmonary hemorrhage suspected
• Vasopressors: If shock persists despite adequate filling (noradrenaline first-line)

Renal Replacement Therapy

Indications: [30]

• Severe AKI with:
  • Oliguria/anuria refractory to fluids
  • Hyperkalemia (> 6.5 mmol/L)
  • Severe metabolic acidosis (pH less than 7.1)
  • Uremia (pericarditis, encephalopathy)
  • Fluid overload (pulmonary edema)

Modality:

• Intermittent hemodialysis (if hemodynamically stable)
• Continuous renal replacement therapy (CRRT) - if shock/unstable

Duration: Usually temporary; renal function typically recovers fully

Prognosis: Complete renal recovery expected in > 95% of survivors

Pulmonary Support

For ARDS/Pulmonary Hemorrhage Syndrome: [18]

• Oxygen therapy: Maintain SpO₂ > 92%
• Mechanical ventilation: Lung-protective strategy
  • Tidal volume 6 ml/kg ideal body weight
  • PEEP optimization
  • Permissive hypercapnia
• Prone positioning: If severe ARDS (P/F ratio less than 150)
• Conservative fluid strategy: Avoid fluid overload
• Consider: ECMO in refractory cases (case reports)

Hemorrhage Management

• Transfusion thresholds:
  • Platelets if less than 20 × 10⁹/L (or less than 50 if bleeding)
  • Packed red cells if Hb less than 70 g/L (or symptomatic)
  • FFP/cryoprecipitate if active bleeding with coagulopathy
• Vitamin K: 10 mg IV (cholestatic coagulopathy)
• Tranexamic acid: Consider if active bleeding (evidence limited)

Other Supportive Measures

• Antipyretics: Paracetamol for fever/myalgia (avoid NSAIDs - bleeding risk)
• Antiemetics: Ondansetron, metoclopramide
• Nutrition: Enteral feeding if tolerated (protein restriction unnecessary)
• Electrolyte correction: Monitor and replace K⁺, Mg²⁺, PO₄³⁻
• Stress ulcer prophylaxis: PPI if mechanically ventilated
• DVT prophylaxis: LMWH if platelets > 50 × 10⁹/L

---

Prophylaxis

Pre-Exposure Prophylaxis

Doxycycline Prophylaxis [31]

• Dose: 200 mg once weekly
• Timing: Start 1-2 days before exposure, continue during exposure, stop 1 week after
• Efficacy: 95% reduction in symptomatic disease (military studies)
• Indications:
  • Military personnel (jungle operations)
  • Short-term high-risk travelers (adventure tourism)
  • Occupational exposure (short-duration)
  • Disaster/flood relief workers

Limitations:

• Not suitable for long-term use (> 3 months)
• Does NOT prevent infection (only reduces symptomatic disease)
• Contraindicated in pregnancy, children less than 8 years

Vaccine Development:

• No licensed human vaccine currently available
• Veterinary vaccines exist (dogs, cattle)
• Human vaccine candidates in development (Cuba, China)

Post-Exposure Prophylaxis

NOT routinely recommended

Consider in special circumstances:

• High-risk exposure (documented outbreak)
• Within 24-48 hours of exposure
• Doxycycline 200 mg single dose (evidence very limited)

---

Monitoring

Inpatient Monitoring

Daily:

• Vital signs (4-6 hourly minimum)
• Urine output (hourly if severe)
• FBC (platelets)
• U&E, creatinine
• Bilirubin

Twice weekly:

• LFTs
• Coagulation
• CK

Clinical:

• Watch for hemoptysis (pulmonary hemorrhage)
• Monitor for oliguria (AKI)
• Assess for meningism
• Bleeding manifestations

---

Special Populations

Pregnancy

Risks: [32]

• Spontaneous abortion (early pregnancy)
• Preterm labor
• Fetal death
• Neonatal infection

Management:

• Avoid doxycycline (teratogenic)
• Use: Penicillin G or amoxicillin
• Dose: Amoxicillin 1 g PO TDS or Penicillin G 1.5 MU IV QDS
• Monitoring: Fetal monitoring, ultrasound
• Delivery: Isolate maternal body fluids

Pediatrics

Epidemiology: Less common but can be severe

Antibiotic choices:

• less than 8 years: Amoxicillin 25-50 mg/kg/day divided TDS (max 1.5 g/day)
• ≥8 years: Doxycycline 2-4 mg/kg/day divided BD (max 200 mg/day)
• Severe disease: Penicillin G 50,000-100,000 units/kg/day divided QDS

Elderly

• Higher risk of severe disease and complications
• Adjust doses for renal function
• Monitor closely for AKI

Renal Impairment

• Dose-adjust antibiotics according to eGFR
• Doxycycline does not require dose adjustment (predominantly biliary excretion)
• Penicillin: Reduce frequency (e.g., Q8H instead of Q6H if GFR 10-50)

---

8. Complications

Pulmonary Hemorrhage Syndrome - Detailed Management

Recognition:

• Day 3-9 of illness
• Sudden dyspnea
• Hemoptysis
• Desaturation
• Bilateral infiltrates on CXR

Urgent Actions:

1. High-flow oxygen → intubation if PaO₂/FiO₂ less than 200
2. Minimize fluids (risk of worsening hemorrhage)
3. Blood products: Platelets, FFP if coagulopathy
4. Mechanical ventilation: Lung-protective
5. Consider: Activated Factor VII (case reports; no RCT evidence)

Predictors of Mortality:

• Age > 40 years
• Oliguria
• Repolarization abnormalities on ECG
• Creatinine > 180 μmol/L
• Alveolar infiltrates on CXR

---

9. Prognosis

Overall Outcomes

Prognostic Factors

Poor Prognosis Indicators: [33]

• Oliguria/anuria
• Pulmonary hemorrhage/hemoptysis
• Arrhythmias
• Hypotension
• Altered consciousness
• Creatinine > 300 μmol/L
• Platelet count less than 50 × 10⁹/L
• Age > 40 years
• Delayed presentation (> 5 days)

Good Prognosis Indicators:

• Anicteric presentation
• Early antibiotic therapy (less than 5 days)
• Young age
• No organ dysfunction

Long-Term Outcomes

Renal: [17]

• Complete recovery expected in > 95% of survivors
• Chronic kidney disease very rare
• Follow-up: Check renal function at 3 and 6 months

Hepatic:

• Complete recovery of liver function (no cirrhosis)
• Liver architecture preserved despite severe acute dysfunction

Pulmonary:

• May have residual restrictive defect if ARDS
• Long-term follow-up spirometry recommended

Ocular:

• Uveitis can occur months-years after recovery (2-10% of cases)
• Requires ophthalmology follow-up if visual symptoms
• Can lead to permanent visual impairment if untreated

Neurological:

• Aseptic meningitis: Complete recovery
• Rare: Persistent headaches, cognitive impairment (encephalitis cases)

General:

• Fatigue common for 2-3 months post-recovery
• Return to full activities: 1-3 months (mild), 3-6 months (severe)

---

10. Prevention & Public Health

Primary Prevention

Personal Protective Measures

Occupational Settings:

• Waterproof boots, gloves, protective clothing
• Avoid hand-to-face contact
• Wound care (cover cuts/abrasions)
• Hand hygiene after animal contact

Recreational Activities:

• Avoid freshwater swimming in endemic areas (especially post-flooding)
• Protective footwear when wading
• Shower immediately after water exposure
• Cover skin abrasions with waterproof dressings

Environmental Measures

• Rodent control (critical)
• Improved sanitation and drainage
• Livestock vaccination (veterinary)
• Occupational health programs for high-risk workers
• Public health warnings during floods/disasters

Outbreak Response

Triggers for Investigation:

• Cluster of cases (> 2 linked by time/place)
• Post-disaster (flood, hurricane)
• Recreational event with water exposure (triathlon, adventure race)

Public Health Actions:

• Case identification and reporting
• Source investigation (environmental sampling)
• Rodent control interventions
• Public awareness campaigns
• Consider prophylaxis for high-risk groups

Notifiable Disease

Leptospirosis is a notifiable disease in many jurisdictions:

• UK: Notify Public Health England (now UKHSA)
• US: Nationally notifiable (CDC)
• Australia: Notify state health departments
• Reporting triggers: Clinical suspicion OR laboratory confirmation

---

11. Guidelines & Evidence

Key International Guidelines

Landmark Evidence

1. Costa F, et al. Lancet Infectious Diseases 2015 [1]

• Global burden of disease meta-analysis
• Estimated 1.03 million cases, 58,900 deaths annually
• Identified high-burden regions and risk factors

2. Bharti AR, et al. Lancet Infectious Diseases 2003 [21]

• Seminal review of leptospirosis pathogenesis and clinical features
• Described biphasic illness pattern and organ-specific pathology

3. Panaphut T, et al. Clinical Infectious Diseases 2003 [26]

• RCT comparing ceftriaxone vs penicillin for severe leptospirosis
• Demonstrated non-inferiority of ceftriaxone

4. Takafuji ET, et al. NEJM 1984 [31]

• Military RCT of doxycycline prophylaxis
• Showed 95% efficacy in preventing symptomatic disease

5. Gouveia EL, et al. PLoS Neglected Tropical Diseases 2008 [18]

• Characterized pulmonary hemorrhage syndrome in Brazil
• Identified risk factors and clinical predictors of mortality

---

12. Exam-Focused Content

Common MRCP/PLAB Exam Scenarios

Scenario 1: Diagnosis

"A 28-year-old farmer presents with 5 days of fever, severe calf pain, and headache. He has bilateral red eyes. Blood tests show: Bilirubin 450 μmol/L, ALT 120 U/L, Creatinine 280 μmol/L, Platelets 80 × 10⁹/L. Most likely diagnosis?"

Answer: Leptospirosis (Weil's disease)

Key learning: Triad of jaundice + AKI + thrombocytopenia, with characteristic low ALT:bilirubin ratio and occupational exposure

Scenario 2: Investigation

"Which test should be performed in the first week of suspected leptospirosis?"

Answer: Blood PCR (or blood culture, though less sensitive)

Rationale: Leptospiremia present in first 7-10 days; serology becomes positive only after day 7-10

Scenario 3: Treatment

"Most appropriate antibiotic for severe leptospirosis with acute kidney injury?"

Answer: IV Penicillin G (or Ceftriaxone)

Not: Oral doxycycline (use in mild disease only)

Scenario 4: Complication

"A patient with leptospirosis develops sudden hemoptysis and bilateral lung infiltrates on day 5. Mortality rate?"

Answer: > 50%

Diagnosis: Pulmonary hemorrhage syndrome - most lethal complication

Viva Voce Points

Opening Statement: "Leptospirosis is a spirochaetal zoonosis caused by Leptospira interrogans, transmitted via contact with water contaminated by rodent urine. It is the most common zoonosis globally, with approximately 1 million cases annually. The clinical spectrum ranges from a mild febrile illness to severe multi-organ failure known as Weil's disease, characterized by jaundice, acute kidney injury, and hemorrhage."

Key Statistics to Quote:

• 1.03 million cases/year globally [1]
• 90% anicteric, 10% severe (Weil's disease) [2]
• Mortality: 5-15% (severe disease), > 50% (pulmonary hemorrhage) [3,18]
• Most common zoonosis worldwide [1]

Pathognomonic Sign: "Conjunctival suffusion - bilateral conjunctival redness WITHOUT discharge, appearing on days 3-4, distinguishing it from bacterial conjunctivitis"

Diagnostic Paradox: "Profound hyperbilirubinemia (> 500 μmol/L) with only modest transaminase elevation (less than 200 U/L), reflecting hepatocellular dysfunction without massive necrosis - this distinguishes leptospirosis from viral hepatitis"

Management Principles:

1. Risk stratification (mild vs severe)
2. Early antibiotics (doxycycline oral for mild; penicillin G IV for severe)
3. Supportive care (RRT for AKI, mechanical ventilation for pulmonary hemorrhage)
4. Anticipate Jarisch-Herxheimer reaction

Prognosis Pearl: "Despite severe acute dysfunction, both liver and kidney typically recover completely in survivors - no chronic cirrhosis or CKD - making aggressive supportive care worthwhile"

Common Mistakes (Avoid to Pass)

❌ Confusing with dengue: Both present with fever, myalgia, thrombocytopenia

• Key differentiator: Conjunctival suffusion and jaundice favor leptospirosis

❌ Missing the diagnosis in anicteric form: 90% of cases are mild and mimic viral illness

• Key: Maintain index of suspicion with water exposure + myalgia + conjunctival suffusion

❌ Ordering wrong test at wrong time: Serology negative in first week

• Remember: PCR/culture in week 1; serology after week 1

❌ Using oral antibiotics in severe disease: Doxycycline only for mild cases

• Severe disease requires: IV penicillin or ceftriaxone

❌ Aggressive fluid resuscitation in pulmonary hemorrhage: Worsens alveolar bleeding

• Use: Conservative fluid strategy

Model Answer: "Describe your approach to a patient with suspected leptospirosis"

"I would approach this systematically with history, examination, investigations, and management.

History: I would establish the epidemiological context - occupational exposure (farmer, sewage worker), recreational water sports (kayaking, swimming), or travel to endemic areas. The timeline is important: leptospirosis typically presents with abrupt fever, severe headache, and myalgia 7-12 days post-exposure. I would specifically ask about calf pain, conjunctival redness, and jaundice.

Examination: I would look for the pathognomonic conjunctival suffusion - bilateral redness without discharge. I would assess for jaundice, signs of bleeding (petechiae, ecchymoses), and check for hepatomegaly and meningism.

Investigations: The choice of test depends on timing. In the first week, I would request blood PCR as the spirochaetes are in the bloodstream. After 7-10 days, serology (MAT or IgM ELISA) becomes positive. I would also check baseline bloods: FBC (thrombocytopenia), U&E (AKI), LFTs (look for the characteristic pattern of high bilirubin with low transaminases), CK (myositis), and urinalysis. If meningism is present, I would perform a lumbar puncture expecting lymphocytic CSF with normal glucose.

Management: I would stratify by severity. For mild, anicteric disease, I would use oral doxycycline 100 mg BD for 7 days. For severe Weil's disease with organ dysfunction, I would admit to HDU/ICU and start IV penicillin G 1.5 million units QDS (or ceftriaxone 1-2 g daily), and provide supportive care including renal replacement therapy if indicated, and lung-protective ventilation if pulmonary hemorrhage develops. I would monitor closely for Jarisch-Herxheimer reaction in the first 4 hours after antibiotics.

Prognosis: I would counsel that with early treatment, prognosis is good, and importantly, both liver and kidney function usually recover completely in survivors, though the acute phase can be severe."

---

13. Patient Information (Layperson Explanation)

What is Leptospirosis?

Leptospirosis (also called Weil's disease in severe cases) is an infection caused by bacteria called Leptospira. These bacteria live in the kidneys of animals - especially rats, but also dogs, cattle, and pigs. The infected animals pass the bacteria out in their urine into water and soil.

How Do You Catch It?

You cannot catch leptospirosis from another person, and it is not spread by rat bites.

You catch it when water or soil contaminated with infected animal urine gets into your body through:

• Cuts or scratches on your skin
• Your eyes, nose, or mouth
• Swallowing contaminated water

Common situations include:

• Swimming or kayaking in rivers, lakes, or canals
• Walking through flood water
• Farming or working with animals
• Working in sewers or drains

What Are the Symptoms?

Leptospirosis usually starts suddenly, 1-2 weeks after exposure, with symptoms similar to severe flu:

Common symptoms:

• High fever and chills
• Severe headache (often behind the eyes)
• Extremely painful muscles - especially in your calves and lower back
• Red eyes (the whites of your eyes turn red but without pus or discharge)
• Feeling sick and vomiting
• Diarrhea

In severe cases (about 1 in 10 people):

• Yellow skin and eyes (jaundice)
• Reduced urine output
• Bleeding (nosebleeds, blood in cough or urine)
• Difficulty breathing
• Confusion

When Should I Seek Medical Help?

See a doctor urgently if:

• You have been in contact with water that might be contaminated (especially after flooding or while doing water sports) AND develop flu-like symptoms
• You develop yellow skin or eyes
• You are passing very little or no urine
• You cough up blood
• You feel confused or very drowsy

How Is It Diagnosed?

Your doctor will:

• Ask about any water or animal contact
• Examine you (especially looking for red eyes and yellow skin)
• Take blood and urine samples for laboratory tests

Special tests:

• In the first week: Blood test (PCR test)
• After the first week: Blood test for antibodies

How Is It Treated?

Mild cases:

• Antibiotic tablets (usually doxycycline or amoxicillin) for 7 days
• Rest and drink plenty of fluids
• Paracetamol for fever and pain
• Most people recover fully in 1-2 weeks

Severe cases:

• Hospital admission (sometimes intensive care)
• Antibiotics through a drip (usually penicillin)
• Support for kidneys (may need temporary dialysis)
• Support for breathing (may need a ventilator)
• Despite severe illness, most people's kidneys and liver recover completely

Can It Be Prevented?

If you work with animals or in sewers:

• Wear protective boots and gloves
• Cover any cuts with waterproof plasters
• Wash hands before eating or smoking

If you do water sports:

• Avoid swimming in rivers or lakes, especially after heavy rain or flooding
• Shower immediately after being in fresh water
• Cover cuts with waterproof plasters
• Avoid getting water in your mouth or eyes

If traveling to high-risk areas:

• Your doctor might prescribe a weekly antibiotic (doxycycline) to prevent infection

What Is the Outlook?

Mild disease (9 out of 10 cases):

• Full recovery expected within 1-2 weeks
• No long-term effects

Severe disease (1 out of 10 cases):

• Can be very serious - some people die (about 1-2 in 10 with severe disease)
• However, if you survive, your kidneys and liver usually recover completely
• Recovery takes 1-3 months
• You may feel tired for several weeks

Important: Even severe leptospirosis does NOT usually cause permanent kidney damage or liver cirrhosis - organs recover fully with treatment.

---

14. References

1. Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003898. doi:10.1371/journal.pntd.0003898

2. Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol. 2015;387:65-97. doi:10.1007/978-3-662-45059-8_5

3. Karpagam KB, Ganesh B. Leptospirosis: a neglected tropical zoonotic infection of public health importance - an updated review. Eur J Clin Microbiol Infect Dis. 2020;39(5):835-846. doi:10.1007/s10096-019-03797-4

4. Lau C, Smythe L, Weinstein P. Leptospirosis: an emerging disease in travellers. Travel Med Infect Dis. 2010;8(1):33-39. doi:10.1016/j.tmaid.2009.12.002

5. Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326. doi:10.1128/CMR.14.2.296-326.2001

6. Daher EF, Silva GB Jr, Silveira CO, et al. Factors associated with thrombocytopenia in severe leptospirosis (Weil's disease). Clinics (Sao Paulo). 2014;69(2):106-110. doi:10.6061/clinics/2014(02)06

7. Dupont H, Dupont-Perdrizet D, Perie JL, et al. Leptospirosis: prognostic factors associated with mortality. Clin Infect Dis. 1997;25(3):720-724. doi:10.1086/513767

8. Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501. doi:10.1111/j.1469-0691.2011.03474.x

9. Pappas G, Papadimitriou P, Siozopoulou V, et al. The globalization of leptospirosis: worldwide incidence trends. Int J Infect Dis. 2008;12(4):351-357. doi:10.1016/j.ijid.2007.09.011

10. Ko AI, Galvão Reis M, Ribeiro Dourado CM, et al. Urban epidemic of severe leptospirosis in Brazil. Lancet. 1999;354(9181):820-825. doi:10.1016/s0140-6736(99)80012-9

11. Lau C, Townend D, Stephenson E, et al. Human leptospirosis infection in Fiji: an eco-epidemiological approach to investigating infectious disease emergence. PLoS Negl Trop Dis. 2016;10(1):e0004372. doi:10.1371/journal.pntd.0004372

12. Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296. doi:10.1016/j.vetmic.2009.03.012

13. Vincent AT, Schiettekatte O, Goarant C, et al. Revisiting the taxonomy and evolution of pathogenicity of the genus Leptospira through the prism of genomics. PLoS Negl Trop Dis. 2019;13(5):e0007270. doi:10.1371/journal.pntd.0007270

14. Gupte MD, Kaur R, Ramachandran R, et al. Human leptospirosis in south-east Asia. Natl Med J India. 2014;27(6):344-352.

15. Haake DA, Matsunaga J. Leptospiral immunoglobulin-like proteins: Characterization of their roles in pathogenesis. Int J Microbiol. 2010;2010:701289. doi:10.1155/2010/701289

16. Seguro AC, Lomar AV, Rocha AS. Acute renal failure of leptospirosis: nonoliguric and hypokalemic forms. Nephron. 1990;55(2):146-151. doi:10.1159/000185938

17. Yang CW. Leptospirosis renal disease: understanding the initiation by Toll-like receptors. Kidney Int. 2007;72(8):918-925. doi:10.1038/sj.ki.5002393

18. Gouveia EL, Metcalfe J, de Carvalho AL, et al. Leptospirosis-associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil. Emerg Infect Dis. 2008;14(3):505-508. doi:10.3201/eid1403.071064

19. Panicker JN, Mammachan R, Jayakumar RV. Primary neuroleptospirosis. Postgrad Med J. 2001;77(911):589-590. doi:10.1136/pmj.77.911.589

20. Edwards CN, Nicholson GD, Hassell TA, et al. Thrombocytopenia in leptospirosis: the absence of evidence for disseminated intravascular coagulation. Am J Trop Med Hyg. 1986;35(2):352-354. doi:10.4269/ajtmh.1986.35.352

21. Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771. doi:10.1016/s1473-3099(03)00830-2

22. Dilrukshi Dassanayake DL, Wimalaratna H, Agampodi SB. Leptospirosis in pregnancy. Ceylon Med J. 2013;58(2):47-50. doi:10.4038/cmj.v58i2.5680

23. Mcbride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr Opin Infect Dis. 2005;18(5):376-386. doi:10.1097/01.qco.0000178824.05715.2c

24. Picardeau M. Diagnosis and epidemiology of leptospirosis. Med Mal Infect. 2013;43(1):1-9. doi:10.1016/j.medmal.2012.11.005

25. Waggoner JJ, Pinsky BA. Molecular diagnostics for human leptospirosis. Curr Opin Infect Dis. 2016;29(5):440-445. doi:10.1097/QCO.0000000000000295

26. Panaphut T, Domrongkitchaiporn S, Vibhagool A, et al. Ceftriaxone compared with sodium penicillin g for treatment of severe leptospirosis. Clin Infect Dis. 2003;36(12):1507-1513. doi:10.1086/375226

27. Guidugli F, Castro AA, Atallah AN. Antibiotics for treating leptospirosis. Cochrane Database Syst Rev. 2000;(2):CD001306. doi:10.1002/14651858.CD001306

28. Suputtamongkol Y, Niwattayakul K, Suttinont C, et al. An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis. Clin Infect Dis. 2004;39(10):1417-1424. doi:10.1086/425001

29. Guerrier G, D'Ortenzio E. The Jarisch-Herxheimer reaction in leptospirosis: a systematic review. PLoS One. 2013;8(3):e59266. doi:10.1371/journal.pone.0059266

30. Daher E, Zanetta DM, Cavalcante MB, Abdulkader RC. Risk factors for death and changing patterns in leptospirosis acute renal failure. Am J Trop Med Hyg. 1999;61(4):630-634. doi:10.4269/ajtmh.1999.61.630

31. Takafuji ET, Kirkpatrick JW, Miller RN, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med. 1984;310(8):497-500. doi:10.1056/NEJM198402233100805

32. Shaked Y, Shpilberg O, Samra D, Samra Y. Leptospirosis in pregnancy and its effect on the fetus: case report and review. Clin Infect Dis. 1993;17(2):241-243. doi:10.1093/clinids/17.2.241

33. Marotto PC, Nascimento CM, Eluf-Neto J, et al. Acute lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated with mortality. Clin Infect Dis. 1999;29(6):1561-1563. doi:10.1086/313501

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult current local guidelines and appropriate specialists for patient care.